Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth

Core Insights - The company reported strong interim results for the first half of 2025, with revenue reaching RMB831.9 million and a gross profit margin of 40.8%, reflecting a significant improvement in operational efficiency and business structure optimization [1] - The CRO business experienced a positive growth trajectory, with revenue increasing by approximately 9.6% year-over-year, driven by a recovery in global biopharmaceutical investments and a surge in domestic innovative drug transactions [2] - The company has successfully expanded its client base, serving 1,669 CRO clients, including all top 10 global pharmaceutical companies, with overseas revenue contributing approximately 85% [3] Financial Performance - Revenue for the first half of 2025 was RMB831.9 million, with a gross profit of RMB339.4 million, leading to a gross profit margin increase of 6.3 percentage points [1] - Net profit amounted to RMB148.6 million, a 3.1% increase year-over-year, while adjusted non-IFRS net profit rose by 9.1% to RMB183.5 million [1] - Langhua Pharmaceutical's revenue reached RMB409.0 million, with an adjusted gross profit margin of 37.9%, reflecting a year-on-year increase of 7.9 percentage points [8] CRO Business Development - The CRO business saw a revenue increase to RMB422.8 million, with adjusted gross profit rising to RMB194.6 million, attributed to improved operational efficiency and a robust order backlog [2] - New modalities accounted for approximately 15% of CRO revenue, growing nearly 19% year-on-year, indicating a shift towards innovative drug development [4] - The company has integrated AI technology into its drug discovery platform, contributing to nearly 10% of total CRO revenue [5][6] CDMO and CMC Business - The company is enhancing its CDMO capabilities through the acquisition of Langhua Pharmaceutical, which has initiated new commercialization projects [7] - Langhua Pharmaceutical's adjusted gross profit margin improved significantly due to structural optimization in its CDMO business [8] - The CMC business has shown significant profitability improvements, with a focus on synthesis and analysis operations [10] Investment and Portfolio Management - The company successfully exited investments from various portfolio companies, generating total proceeds of nearly RMB76.5 million [12] - As of June 30, 2025, the company had invested in 93 portfolio companies, with a significant portion located in North America [12][13] - The company is actively participating in establishing an RMB-denominated fund to support biopharmaceutical ventures [15] Infrastructure and Workforce - As of June 30, 2025, the company employed 2,085 staff, with a significant number dedicated to CRO R&D [16] - The company has expanded its facilities, including a new headquarters in Shanghai and multiple parks for R&D and production [17][18] - The Shanghai Supercomputing Center has been operational, supporting advanced drug discovery computations [19] Strategic Vision - The company aims to strengthen the synergy between its CRO and CDMO businesses, enhancing its one-stop innovative drug R&D platform [20] - Future plans include boosting revenue growth and profitability through strategic partnerships and improved operational efficiencies [11][22]